EP-1071: Maintenance metronomic chemotherapy for recurrent/metastatic nasopharyngeal carcinoma  by Wu, C. et al.
ESTRO 35 2016                                                                                                                                                    S515 
________________________________________________________________________________ 
of primary tumor volume for its prognostic impact and for 
treatment stratification in future clinical trials. 
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Purpose or Objective: To investigate the role of plasma EBV 
(pEBV) DNA and serum antibodies tests in nasopharyngeal 
carcinoma (NPC) screening. 
 
Material and Methods: From Feb. 2008 to Nov. 2009, a total 
of 467 subjects coming to an otorhinolaryngology outpatient 
clinic were enrolled in a prospective screening study. Paired 
serum and plasma samples were collected and subjected to 
an immunofluorescence assay for IgA antibodies against the 
viral capsid antigen (VCA) and early antigen (EA) and a real-
time quantitative polymerase chain reaction assay for pEBV 
DNA measurement. Nasopharyngoscopy was done for subjects 
with risk factors associated with NPC or abnormal reports of 
blood tests. Biopsy was performed for suspected lesions to 
confirm the diagnosis. 
 
Results: We divided the studied population into three 
subgroups- group A (n=139, symptoms/signs mimicking NPC, 
presence of family history of NPC, or abnormal antibody tests 
at other hospital), group B (n=191, symptoms/signs not 
related to NPC), and group C (n=137, healthy volunteers). 
After a minimal follow-up of five years, 9 of 467 screened 
subjects were proven to have NPC. All NPC patients were 
found in the group A. The sensitivity, specificity, positive 
predictive value, and negative predictive value for the pEBV 
DNA test were 100%, 99.8%, 90.0%, and 100%. The sensitivity, 
specificity, positive predictive value, and negative predictive 
value for the VCA-IgA test were 77.8%, 88.9%, 12.1%, and 
99.5%. The corresponding numbers for the EA-IgA test were 
33.3%, 97.6%, 21.4%, and 98.7%. 
 
Conclusion: The pEBV DNA test is a useful screening tool in 
the detection of NPC. Both VCA-IgA and EA-IgA antibody tests 
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Purpose or Objective: The aim of this study is to evaluate 
the prognostic value of metabolic parameters derived from 
18F-FDG PET-CT performed before definitive radiation 
therapy (RT) (prePET) in patients with mucosal-primary head 
and neck squamous-cell-carcinoma (MPHNSCC) and to assess 
the additive prognostic values of 18F-FDG PET-CT performed 
during RT (iPET).  
 
Material and Methods: One hundred consecutive patients 
who had radical RT for MPHNSCC and underwent staging 
prePET and iPET performed during the third week of 
treatment, were retrospectively analysed. The maximum-
standardised-uptake-value (SUVmax), metabolic-tumour-
volume (MTV) and total-lesional-glycolysis (TLG) of primary 
tumour were analysed for both prePET and iPET, and results 
were correlated with oncological outcomes including loco-
regional-recurrence-free-survival (LRFS), disease-free-
survival (DFS), metastatic-failure-free survival (MFFS) and 
overall-survival (OS), using Kaplan-Meier analysis. Optimal-
cutoffs (OC) were derived from Receiver-Operating-
Characteristic curves for the best combined sensitivity and 
specificity. 
 
Results: Median age was 61 years (range 39-81), median 
follow-up of 20 months (range 4-70, mean 27), and AJCC 7th 
Edition clinical stage II, III and IV were 8, 24 and 68 patients 
respectively. All patients in this study received definitive RT 
using IMRT or TomoTherapy®: 15 patients were treated with 
RT only; 68 patients with chemoradiotherapy; 17 patients 
with RT and concurrent Cetuximab; and 17 patients received 
induction chemotherapy. Addition of iPET significantly 
improves the prognostic values of all three metabolic 
parameters. Metabolic values below cutoffs in both prePET 
and iPET (comPET) were found to be associated with 
significant improvements in DFS (p<0.01), LRFS (p<0.05) and 
OS (p<0.05). In addition, patients with SUVmax above the OC 
in comPET were associated with worse MFFS (p = 0.011) and 
confirmed on both univariate (p=0.019) and multivariate 
analyses (p=0.04). 
 
Conclusion: The predictive value of FDG-PET is significantly 
improved by addition of iPET. ComPET is found to be 
predictive of oncological outcomes including MFFS and can 
potentially be used in future adaptive local and systemic 
therapy trials.  
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Purpose or Objective: The prognosis of recurrent/metastatic 
nasopharyngeal carcinoma (r/m NPC) after curative 
radiotherapy is very poor. We aim to investigate the survival 
impact and toxicity of maintenance metronomic 
chemotherapy in patients with r/m NPC. 
 
Material and Methods: Patients with r/m NPC were first 
salvaged by iv cisplatin-based or gemcitabine-based 
chemotherapy. Local therapy (either radiotherapy or surgery) 
was administered for suitable patients and feasible disease 
(local tumor or oligometastasis) as a local consolidation boost 
therapy. We started to give maintenance chemotherapy with 
oral tegafur-uracil (two capsules per day) with/without oral 
cyclophosphamide 50 mg per day for at least 12 months or 
until disease progression/intolerable toxicity/patient’s 
refusal in our hospital since 2005. A total of 89 patients were 
collected. We analyzed the treatment outcome between 
patients with (n=45) and without (n=44) maintenance 
chemotherapy. 
 
Results: Baseline patient characteristics at diagnosis of 
recurrence/metastasis (age, sex, pathological type, 
performance status, disease extent) and response to 
antecedent iv salvage chemotherapy were comparable in 
both arms. The median overall survival for patients with and 
without maintenance chemotherapy were 26 and 11 months, 
respectively (P<0.01). We observed 5 and 1 patients with 
biopsy-proven distant metastasis surviving more than 5 years 
and no evidence of disease in patients with and without 
maintenance chemotherapy. The toxicities during 
maintenance oral chemotherapy period were usually mild and 
no occurrence of grade 3/4 non-hematolocal toxicity. 
 
Conclusion: Maintenance metronomic chemotherapy strategy 
significantly improves overall survival and has low toxicity in 
patients with r/m NPC after iv salvage chemotherapy. 
